University of Bologna, Italy

Associate Professor

Email: roberto.manfredi@unibo.it

Qualifications

1992 Postdoctoral Diploma of Specialist, University of Bologna, Infectious Diseases

1988 M.D., University of Bologna

Publications (selected)

1. D. De Ronchi, I. Faranca, D. Berardi, P. Scudellari, M. Borderi, R. Manfredi, L. Fratiglioni. Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors. Archives of Neurology 2002; 59: 812-818.
2. R. Manfredi, R. Motta, D. Patrono, L. Calza, F. Chiodo, P. Boni. A prospective case-control survey of laboratory markers of skeletal muscle damage during HIV disease and antiretroviral therapy. AIDS 2002; 16:1969-1972; erratum in AIDS 2003; 17: 145.
3. L. Calza, R. Manfredi, F. Chiodo. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003; 17:851-859.
4. R. Manfredi. HIV infection, antiretroviral therapy, and hepatic function. Emerging epidemiological, pathogenetic, and clinical issues, and their consequences on disease management. AIDS 2003; 17: 2253-2256.
5. R. Manfredi., A. Nanetti, M. Tadolini, L Calza, S. Morelli, M. Ferri, G. Marinacci. Role of Mycobacterium xenopi disease in patients with HIV infection at the time of highly active antiretroviral therapy (HAART), Comparison with the pre-HAART period. Tuberculosis 2003; 83: 319-328.
6. L. Calza, R. Manfredi, F. Chiodo. Infective endocarditis: a review of the best treatment options. Expert Opinion on Pharmacotherapy 2004; 5: 1899-1916.
7. R. Manfredi. HIV infection and advanced age. Emerging epidemiological, clinical, and management issues. Ageing Research Reviews 2004; 3: 31-54.
8. R. Manfredi, L. Calza, F. Chiodo. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. Journal of Acquired Immune Deficiency Syndromes 2004; 5: 492-502.
9. R. Manfredi, A. Nanetti, R. Valentini, M. Ferri, S. Morelli, L. Calza. Epidemiological, clinical and therapeutic features of AIDS-related Mycobacterium kansasii infection during the HIV pandemic: an 11-year follow-up study. HIV Medicine 2004; 5: 431-436.
10. R. Manfredi, L. Calza, F. Chiodo. Changing epidemiology of hepatitis A in tbe Bologna metropolitan area, northern Italy: importance of conselling and prophylactic mesures for the male homo/bisexual population. Clinical Microbiology and Infection 2005; 11: 845-848.
11. R. Manfredi. High-risk dysmetabolism disorders associated with HAART-treated HIV disease, and reimbursement of lipid-lowering drugs, in a clinical and socio-economic perspective. AIDS Reviews 2005; 7: 155-160.
12. R. Manfredi, S. Sabbatani. A novel antiretroviral class (Fusion Inhibitors) in the management of HIV infection. Present features and future perspectives of Enfuvirtide (T-20). Current Medicinal Chemistry 2006; 13: 2369-2384.
13. R. Manfredi, L. Calza, F. Chiodo. Primary Cytomegalovirus infection in otherwise healthy adults with fever of unknown origin: a 3-year prospective survey. Infection 2006; 34: 87-90.
14. R. Manfredi, L. Calza, F. Chiodo. Prolonged statin administration does not act on the cell-mediated immunity of HIV-infected dyslipidemic patients treated with a steady and effective highly active antiretroviral therapy. A two-year prospective study of statin versus fibrate administration, versus a dietary/exercise program. Journal of Biological Regulators and Homeostatic Agents 2006; 20: 1-9.
15. R. Manfredi, S. Sabbatani, S. Bergonzi. Clinical ritonavir and lopinavir hypersensitivity confirmed by a specific in vitro cellular allergen stimulation test. Current HIV Research 2007; 5: 440-442.
16. R. Manfredi, L. Calza. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives on antiretroviral-naïve and -experienced patients. AIDS Patient Care and STDs 2008; 22: 279-290.
17. L. Calza, R. Manfredi, D. Pocaterra, F. Chiodo. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. Journal of Infection 2008; 57: 16-32.
18. R. Manfredi, G. Marinacci, L. Calza, B. Passarini. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration. International Journal of Antimicrobial Agents 2008; 31: 590-592.
19. R. Manfredi. Multicentre inter-cohort studies – reliable responses for HIV disease management? AIDS Reviews 2009; 11: 53-55.
20. L. Calza, R. Manfredi, V. Colangeli, D. Pocaterra, N. Rosseti, M. Pavoni, F. Chiodo. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care and STDs 2009; 23: 691-697.
21. R. Manfredi, A. Nanetti, P. Dal Monte, L. Calza. Increasing pathomorphism of pulmonary tuberculosis: an observational study of slow clinical, microbiological and imaging response of lung tuberculosis to specific treatment. Which role for linezolid? Braz J Infect Dis. 2009; 13: 297-303.
22. L. Calza, R. Manfredi R, G. Verucchi. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS. 2010; 24: 789-802.
23. L. Calza, R. Manfredi. Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection. Curr HIV Research 2012; 10: 661-672.
24. L. Calza, F. Trapani, C. Salvadori, E. Magistrelli, R. Manfredi, V. Colangeli, M.A. Di Bari, M. Borderi, P. Viale. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir. Scandinavian Journal of Infectious Diseases 2013; 45: 147-154.
25. L. Calza, R. Manfredi, V. Colangeli, F.F. Trapani, C. Salvadori, E. Magistrelli, I. Danese, G. Verucchi, C. Serra, P. Viale. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Research and Human Retroviruses 2013; 29: 547-56.

Profile Details

http://www.unibo.it/docenti/roberto.manfredi